AC Immune (ACIU) Consolidated Net Income (2015 - 2026)

AC Immune (ACIU) has reported Consolidated Net Income for 12 consecutive years, with -$18.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income rose 10.7% year-over-year to -$18.9 million; the TTM figure through Mar 2026 stood at -$82.3 million (down 41.87% YoY), while the FY2025 annual figure was -$85.0 million, down 46.21% from the prior year.
• Consolidated Net Income retreated to -$18.9 million in Q1 2026 per ACIU's latest filing, from -$18.0 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $6.4 million in Q3 2024 and bottomed at -$25.6 million in Q2 2025.
• Historically, Consolidated Net Income has averaged -$17.4 million across 5 years, with a median of -$18.9 million in 2023.
• Annual changes were most pronounced in 2024 — Consolidated Net Income soared 137.06% — and 2025, when it tumbled 412.11%.
• AC Immune's Consolidated Net Income stood at -$19.5 million in 2022, then jumped by 72.53% to -$5.3 million in 2023, then slumped by 237.25% to -$18.0 million in 2024, then increased by 0.26% to -$18.0 million in 2025, then declined by 5.1% to -$18.9 million in 2026.
• Business Quant data shows ACIU's Consolidated Net Income at -$18.9 million in Q1 2026, -$18.0 million in Q4 2025, and -$19.8 million in Q3 2025.